{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:08Z","timestamp":1790934368100,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI166059"],"award-info":[{"award-number":["U19AI166059"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coccidioides meningitis is a life-threatening complication with Coccidioides spp that requires lifelong antifungal therapy. While some cases respond to azoles, others are refractory and require periodic treatment with intravenous and\/or intrathecal (IT) amphotericin B. MAT2203 is a novel formulation of amphotericin B that uses a rolled phosphatidylserine lipid nanocrystal bilayer that is orally absorbed. MAT2203 has been successfully used to treat cryptococcal meningitis and Histoplasma meningitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>In 2017 a previously healthy construction worker developed coccidioidal pneumonia and meningitis and was treated with liposomal amphotericin B and oral fluconazole. His pneumonia resolved, but his meningitis worsened. Imaging showed vasculitis of his middle cerebral artery and arachnoiditis at the base of the brain and eventually throughout his spine. He required multiple changes in azoles and eventually an Ommaya reservoir so that he could receive periodic IT amphotericin B plus corticosteroids while continuing oral isavuconazole. Treatment response was monitored with symptoms, cerebral spinal fluid (CSF) cell counts, CSF Coccidioides antigen, and imaging. Frequency of IT treatment varied over the course of his illness from 3 times per week to monthly, increasing with symptom flares. A trial of the investigational antifungal olorofim also failed. In 2024, 1 month after his last dose of IT amphotericin B, the patient started treatment with MAT2203. After 6 months of MAT2203 (without any IT or intravenous amphotericin B), Coccidioides antigen in the ventricular CSF was undetectable for the first time and remained so with normalization of glucose and cell counts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MAT2203 may offer an oral therapeutic option for refractory cases of Coccidioides meningitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag075","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:42:44Z","timestamp":1770986564000},"source":"Crossref","is-referenced-by-count":2,"title":["Successful Control of Refractory\n                    <i>Coccidioides<\/i>\n                    Meningitis With MAT2203"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2028-8158","authenticated-orcid":false,"given":"Sanjay R","family":"Mehta","sequence":"first","affiliation":[{"name":"Department of Medicine, San Diego Veterans Affairs Medical Center , San Diego, California ,","place":["USA"]},{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Johns","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, San Diego Veterans Affairs Medical Center , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Matkovits","sequence":"additional","affiliation":[{"name":"Matinas Biopharma , Bridgewater, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Matinas Biopharma , Bridgewater, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-5279","authenticated-orcid":false,"given":"Joshua","family":"Fierer","sequence":"additional","affiliation":[{"name":"Department of Medicine, San Diego Veterans Affairs Medical Center , San Diego, California ,","place":["USA"]},{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026030606365083700_ofag075-B1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.idc.2021.03.010","article-title":"Coccidioidomycosis","volume":"35","author":"Bays","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2026030606365083700_ofag075-B2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/ciac478","article-title":"Controversies in the management of central nervous system coccidioidomycosis","volume":"75","author":"Thompson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026030606365083700_ofag075-B3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026030606365083700_ofag075-B4","doi-asserted-by":"crossref","first-page":"ofae346","DOI":"10.1093\/ofid\/ofae346","article-title":"Oral lipid nanocrystal amphotericin B (MAT2203) for the treatment of invasive fungal infections","volume":"11","author":"Dalton","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026030606365083700_ofag075-B5","doi-asserted-by":"crossref","first-page":"e02130-17","DOI":"10.1128\/AAC.02130-17","article-title":"Posaconazole-induced pseudohyperaldosteronism","volume":"62","author":"Kuriakose","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030606365083700_ofag075-B6","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026030606365083700_ofag075-B7","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/AAC.00593-15","article-title":"Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models","volume":"59","author":"Shubitz","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"2026030606365083700_ofag075-B8","doi-asserted-by":"crossref","first-page":"e01715-18","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030606365083700_ofag075-B9","doi-asserted-by":"crossref","first-page":"e00999-18","DOI":"10.1128\/AAC.00999-18","article-title":"The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030606365083700_ofag075-B10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026030606365083700_ofag075-B11","first-page":"e87716","article-title":"Disseminated musculoskeletal coccidioidomycosis in an immunocompetent host: a rare case requiring extensive spinal and pelvic surgery","volume":"17","author":"Raman","year":"2025","journal-title":"Cureus"},{"key":"2026030606365083700_ofag075-B12","doi-asserted-by":"crossref","first-page":"ofae010","DOI":"10.1093\/ofid\/ofae010","article-title":"MSG-15: super-bioavailability itraconazole versus conventional itraconazole in the treatment of endemic mycoses-a multicenter, open-label, randomized comparative trial","volume":"11","author":"Spec","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026030606365083700_ofag075-B13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jof6020066","article-title":"Encochleated amphotericin B: is the oral availability of amphotericin B finally reached?","volume":"6","author":"Aigner","year":"2020","journal-title":"J Fungi (Basel)."}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag075\/66956837\/ofag075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag075\/66956837\/ofag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag075\/66956837\/ofag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:36:57Z","timestamp":1772797017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag075\/8488424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag075","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,16]]},"article-number":"ofag075"}}